Katz N
Pain Rep. 2021; 6(1):e845.
PMID: 33511323
PMC: 7837951.
DOI: 10.1097/PR9.0000000000000854.
Peck C
J Pharmacokinet Pharmacodyn. 2010; 37(6):617-28.
PMID: 20978827
DOI: 10.1007/s10928-010-9171-3.
Shah R
Drug Saf. 2007; 30(12):1093-110.
PMID: 18035863
DOI: 10.2165/00002018-200730120-00003.
Riley R, Parker A, Trigg S, Manners C
Pharm Res. 2001; 18(5):652-5.
PMID: 11465421
DOI: 10.1023/a:1011085411050.
Bournique B, Lambert N, Boukaiba R, Martinet M
Br J Clin Pharmacol. 2001; 52(1):53-63.
PMID: 11453890
PMC: 2014500.
DOI: 10.1046/j.0306-5251.2001.01413.x.
Drug-drug pharmacodynamic interaction detection by a nonparametric population approach. Influence of design and of interindividual variability.
Merle Y, Mallet A, SCHMAUTZ E
J Pharmacokinet Biopharm. 2000; 27(5):531-54.
PMID: 10948697
DOI: 10.1023/a:1023290530853.
Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.
Prakash C, Kamel A, Cui D, Whalen R, Miceli J, Tweedie D
Br J Clin Pharmacol. 2000; 49 Suppl 1:35S-42S.
PMID: 10771452
PMC: 2015052.
DOI: 10.1046/j.1365-2125.2000.00151.x.
Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate.
Walker B, Valenzuela S, Singleton C, Tie H, Bursill J, Wyse K
Br J Pharmacol. 1999; 127(1):243-51.
PMID: 10369479
PMC: 1565989.
DOI: 10.1038/sj.bjp.0702502.
Inhibition and induction of cytochrome P450 and the clinical implications.
Lin J, Lu A
Clin Pharmacokinet. 1998; 35(5):361-90.
PMID: 9839089
DOI: 10.2165/00003088-199835050-00003.
The effect of RPR 102341 on theophylline metabolism and phenacetin O-deethylase activity in human liver microsomes.
White R, Heyn H, Stevens J
Pharm Res. 1997; 14(4):512-5.
PMID: 9144741
DOI: 10.1023/a:1012163919636.
Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans.
Wilkinson G
J Pharmacokinet Biopharm. 1996; 24(5):475-90.
PMID: 9131486
DOI: 10.1007/BF02353475.
The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.
Kivisto K, Kroemer H, Eichelbaum M
Br J Clin Pharmacol. 1995; 40(6):523-30.
PMID: 8703657
PMC: 1365206.
DOI: 10.1111/j.1365-2125.1995.tb05796.x.
Polypharmacy. Pharmacokinetic perspectives.
Honig P, Cantilena L
Clin Pharmacokinet. 1994; 26(2):85-90.
PMID: 8162659
DOI: 10.2165/00003088-199426020-00001.
Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences.
Kivisto K, Neuvonen P, Klotz U
Clin Pharmacokinet. 1994; 27(1):1-5.
PMID: 7955768
DOI: 10.2165/00003088-199427010-00001.
Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine.
von Moltke L, Greenblatt D, Harmatz J, Shader R
Br J Clin Pharmacol. 1994; 38(1):23-31.
PMID: 7946933
PMC: 1364833.
DOI: 10.1111/j.1365-2125.1994.tb04317.x.
Progress in the drug management of allergic rhinitis.
Mygind N
Eur Arch Otorhinolaryngol. 1995; 252 Suppl 1:S68-72.
PMID: 7734978
DOI: 10.1007/BF02484439.
Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers.
Yang T, Prakash C, Roden D, Snyders D
Br J Pharmacol. 1995; 115(2):267-74.
PMID: 7670728
PMC: 1908306.
DOI: 10.1111/j.1476-5381.1995.tb15873.x.
